Buprenorphine
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
Buprenorphine: From Opioid Dependence to Acute Intermittent Porphyria
One-Sentence Summary
Buprenorphine (supplied in New Zealand as a buprenorphine/naloxone sublingual tablet) was originally used to treat opioid dependence. The TxGNN model predicts it may be effective for acute intermittent porphyria, but there are 0 clinical trials and only 1 publication (a 1993 anaesthetic case report), so the evidence is very weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Opioid dependence (substance abuse/dependence, morphine dependence), based on the knowledge graph; no approved indication text is available from the New Zealand licences |
| Predicted New Indication | Acute intermittent porphyria |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L4 |
| New Zealand Market Status | Cancelled only (no currently valid authorisation) |
| Number of Authorizations | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, buprenorphine is a mu-opioid partial agonist (also a kappa antagonist), and its efficacy in opioid dependence is established. No mechanistic link to the new indication is supported by the data compiled for this report.
The only publication retrieved is a 1993 report on anaesthetic management of a patient with acute intermittent porphyria. It concerns peri-operative drug safety, not treatment of the disease. Buprenorphine has no known connection to heme biosynthesis, the pathway disrupted in this condition. The very high TxGNN score (0.994) is therefore not corroborated by clinical or mechanistic evidence, and likely reflects relationships in the knowledge graph rather than a true therapeutic effect.
Other predictions were also reviewed. All remain at the "Hold" stage:
- Lingual-facial-buccal dyskinesia (score 99.32%, L4): the literature is mostly off-topic (dementia agitation, pain management, animal and pharmacology studies). Opioid-related movement effects could even be adverse.
- Chronic tic disorder (99.13%, L5), continuous spikes and waves during sleep (99.05%, L5), benign shuddering attacks (99.03%, L5) and extrapyramidal and movement disease (99.03%, L5): prediction only, with no trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8301837 | 1993 | Case report | Masui (Japanese Journal of Anesthesiology) | Anaesthetic management of a woman with suspected acute intermittent porphyria undergoing surgery for ovarian tumour; addresses peri-operative safety, not treatment of the disease |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2574012 | Buprenorphine Naloxone BNM | Sublingual tablet 8 mg with naloxone 2 mg | Not available (cancelled) |
| 2574004 | Buprenorphine Naloxone BNM | Sublingual tablet 2 mg with naloxone 0.5 mg | Not available (cancelled) |
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): these include respiratory conditions (chronic obstructive pulmonary disease, respiratory failure), liver disease and chronic viral hepatitis (B and C), gallbladder disease, QT-related conditions (long QT syndrome, torsades de pointes), orthostatic hypotension, adrenal insufficiency (Addison disease), hypothyroidism/myxedema, gastrointestinal obstruction (paralytic ileus, intestinal obstruction), benign prostatic hyperplasia, urethral stricture, raised intracranial pressure (pseudotumor cerebri, intracranial hypertension), and drug dependence or substance-related disorders. Treat these as signals to verify against the package insert.
- Drug Interactions: 264 interactions were identified. Major-level examples include alvimopan, bupropion, morphine, cisapride and dolasetron. Moderate-level examples include famotidine, hyoscyamine, loperamide, aprepitant, atropine, dexamethasone, cimetidine and clarithromycin.
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials, and the single publication is an anaesthetic case report unrelated to treatment. No mechanism links buprenorphine to acute intermittent porphyria. All New Zealand authorisations are cancelled. The knowledge graph also flags many disease-level contraindications.
To proceed, the following is needed:
- Mechanism of action data and a plausible biological rationale for the predicted indication
- Package insert warnings and contraindications (e.g. from Medsafe) for safety screening
- Evidence that buprenorphine is safe in acute intermittent porphyria (porphyria safety classification of the drug)
- Preclinical or clinical studies directly testing efficacy in the predicted indication
- Clarification of the regulatory and supply pathway, since no valid New Zealand authorisation exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.